The HER2 amplification for colorectal cancer enhanced stratification (HERACLES) trial was a multicenter, open-label Phase II clinical trial in patients with CRC resistant to chemotherapy and anti-EGFR therapy. The gene discussed is EGFR; the disease is colorectal carcinoma.